Gilead Sciences (GILD), Lakefront Biotherapeutics Acquire Ouro Medicines to Advance Autoimmune Pipeline

Gilead Sciences Inc. (NASDAQ:GILD) is one of the best quality growth stocks to buy. On June 4, Gilead Sciences and Lakefront Biotherapeutics completed the acquisition of Ouro Medicines, a strategic move designed to bolster their inflammation and immunology pipelines. The centerpiece of this acquisition is gamgertamig (OM336), a clinical-stage T cell engager being developed as a potential first-in-class treatment for severe, antibody-mediated orphan autoimmune diseases like AIHA and ITP.

Under the partnership agreement, Lakefront will manage ongoing and future Phase 1/2 clinical studies for gamgertamig, while Gilead leads registrational and late-stage development. Gilead holds sole global commercialization rights, with Lakefront entitled to tiered royalties ranging from 20% to 23%. Additionally, Lakefront has secured three preclinical autoimmune programs from Ouro, with Gilead maintaining an opt-in right for a future profit-sharing collaboration.

Gilead Sciences (GILD), Lakefront Biotherapeutics Acquire Ouro Medicines to Advance Autoimmune Pipeline

BlurryMe/Shutterstock.com

This transaction supports Gilead’s objective of advancing therapies that move beyond chronic disease management toward durable immune reset. The acquisition also provides Lakefront with the operational assets and research foundation to accelerate its own development pipeline, with the company projecting a strong cash balance of ~€2 billion by the end of 2026 to support further strategic initiatives.

Gilead Sciences Inc. (NASDAQ:GILD) is a drug manufacturer that develops medicines for unmet medical needs. The company provides treatments for HIV-1, chronic hepatitis C, primary biliary cholangitis, chronic hepatitis B, and serious invasive fungal infections. It also offers T-cell and CAR T-cell therapies for adult patients, intravenous injections, and treatments for COVID-19.

While we acknowledge the risk and potential of GILD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GILD and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1